Colleen Kusy
Stock Analyst at Baird
(0.93)
# 3,226
Out of 4,667 analysts
39
Total ratings
30%
Success rate
-17.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELVN Enliven Therapeutics | Maintains: Outperform | $32 → $40 | $25.43 | +57.29% | 2 | Nov 15, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $27.50 | +136.36% | 2 | Nov 13, 2024 | |
| CHRS Coherus BioSciences | Maintains: Outperform | $8 → $4 | $1.10 | +263.64% | 4 | Nov 8, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $92 → $55 | $27.49 | +100.07% | 10 | Nov 7, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $4 → $3 | $2.22 | +35.14% | 4 | Aug 14, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $18 → $17 | $8.78 | +93.62% | 4 | Aug 8, 2024 | |
| OCS Oculis Holding AG | Maintains: Outperform | $35 → $37 | $14.91 | +148.16% | 3 | Jun 11, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $27 → $25 | $8.74 | +186.04% | 1 | Mar 12, 2024 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $91.17 | +15.17% | 1 | Feb 23, 2024 | |
| AGEN Agenus | Initiates: Outperform | $160 | $2.67 | +5,892.51% | 1 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $14 | $0.78 | +1,706.45% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $8.14 | +317.69% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $3.06 | +7,416.34% | 1 | Nov 2, 2021 |
Enliven Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $32 → $40
Current: $25.43
Upside: +57.29%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $27.50
Upside: +136.36%
Coherus BioSciences
Nov 8, 2024
Maintains: Outperform
Price Target: $8 → $4
Current: $1.10
Upside: +263.64%
Apellis Pharmaceuticals
Nov 7, 2024
Maintains: Outperform
Price Target: $92 → $55
Current: $27.49
Upside: +100.07%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $2.22
Upside: +35.14%
Ocular Therapeutix
Aug 8, 2024
Maintains: Outperform
Price Target: $18 → $17
Current: $8.78
Upside: +93.62%
Oculis Holding AG
Jun 11, 2024
Maintains: Outperform
Price Target: $35 → $37
Current: $14.91
Upside: +148.16%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $8.74
Upside: +186.04%
Nuvalent
Feb 23, 2024
Initiates: Outperform
Price Target: $105
Current: $91.17
Upside: +15.17%
Agenus
Jun 6, 2023
Initiates: Outperform
Price Target: $160
Current: $2.67
Upside: +5,892.51%
Aug 5, 2022
Maintains: Outperform
Price Target: $17 → $14
Current: $0.78
Upside: +1,706.45%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $8.14
Upside: +317.69%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $3.06
Upside: +7,416.34%